Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Amylin Jumps on Word of Bristol-Myers Offer

By Pharmaceutical Processing | March 29, 2012

NEW YORK (AP) — Shares of Amylin Pharmaceuticals Inc. surged more than 54 percent Wednesday on a report the diabetes drug maker recently turned down a buyout offer from Bristol-Myers Squibb Co. worth $3.5 billion.

Bloomberg News reported that Bristol-Myers proposed to buy Amylin for $22 per share. It said there have been no talks between the companies since the initial offer earlier this year. Bristol-Myers Squibb and Amylin declined to comment on the story, which cited anonymous sources.

Amylin shares rose $8.38, or 54.5 percent, to close at $23.77. Earlier the shares peaked at $24.09, their highest price since August 2008.

In February Bristol-Myers bought hepatitis C drugmaker Inhibitex for $2.5 billion. The New York company’s biggest sellers include the oral diabetes treatment Onglyza, and the psychiatric drug Abilify. Bristol-Myers markets blood thinner Plavix through a partnership with French drugmaker Sanofi, and while Plavix is the second-best selling drug in the world, it will lose U.S. patent protection in May. Its 2011 revenue amounted to $21.24 billion, compared with Amylin’s revenue of $650.7 million.

Bristol-Myer’s shares ended unchanged at $33.67.

Amylin makes the twice-a-day diabetes drug Byetta and a newer once-a-week version called Bydureon. Both drugs were marketed through a partnership with Eli Lilly and Co., but the companies announced in November that they were ending their partnership. Amylin is taking over marketing both products outside the U.S., and it has been looking for a new partner to help sell the drugs.

Amylin also makes a diabetes drug called Symlin.

 

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards